He Ignored Double Vision… The Damage Came Later. A story about delayed MS diagnosis by @aaronbostermd.bsky.social youtu.be/uvpN18SDYSw?...

NVG-291 youtube.com/shorts/g48eN...

Upcoming videos: 4/22/26: MS drug Classes 4/29/26: Dr. Boster is right about THIS 5/6/26: THIS gets misdiagnosed as MS 5/13/26: 9 Stupid things doctors believed about MS. Let me know if you have other video ideas www.youtube.com/@DrBrandonBe...

Low vitamin D in multiple sclerosis is linked to higher rates of relapses, but these is no clear association with disability (as measured by EDSS) according to this meta-analysis pubmed.ncbi.nlm.nih.gov/41983136/

Multiple Sclerosis, the Gut, and Entyvio. A Fascinating Study. youtu.be/XwGr6wn8u30?...

Multiple sclerosis disease duration vs. level of disability. There is a correlation but perhaps not as strong as you might expect. From North American Research Committee on Multiple Sclerosis (NARCOMS) www.neurology.org/doi/10.1212/...

As a reminder, the benefits of IV steroids over oral steroids are largely psychological. Concentrations in the blood of IV methylprednisolone (solumedrol) and oral prednisone are similar by 4 hours. pubmed.ncbi.nlm.nih.gov/15452302/

The medical mystery of "wearing off effect" between doses of tysabri/tyruko (feeling worse MS symptoms between doses). Reported symptoms do not significantly correlate with receptor saturation. pubmed.ncbi.nlm.nih.gov/41965149/

An explanation of Adult Onset Leukodystrophy which can mimic multiple sclerosis by Dr. Manzoor Ahmed l youtu.be/DL5HnSL8cNw?...

44-year-old woman with vision loss/confusion. MRI brain shows enhancing periventricular lesions. Multiple Sclerosis? No! Diagnosis? Prepare to fail miserably

Microglial activation in the brain as measured by TSPO PET scan (left) may have a stronger correlation with disability in multiple sclerosis than T1 dark lesions ("black holes," right) journals.lww.com/co-neurology...

Christina Applegate Autobiography "You with the Sad Eyes" Reviewed by Neurologist youtu.be/iJd1CH9qmcc?...

The STRATA dataset. Those with multiple sclerosis originally randomized to tysabri had less disability than those randomized to placebo even many years later, suggesting early treatment does make a difference. pmc.ncbi.nlm.nih.gov/articles/PMC...

How strong is the correlation between industry payments to doctors and prescribing brand name drugs over generics? This study found receiving > $1000 was linked to about a 4-fold increased use of copaxone over generic glatiramer www.neurology.org/doi/10.1212/...

A paramagnetic rim lesion in a juxtacortical lesion with a dark edge (upper left) in multiple sclerosis seen on 7T MRI. academic.oup.com/braincomms/a...

Considerations for family planning with multiple sclerosis. Authors @drruthdobson @KerstinHellwig pubmed.ncbi.nlm.nih.gov/41925496/

50 year old man with migraine w/aura with vision loss and thinning of the retinal nerve fiber layer on OCT. MRI showed this. Multiple sclerosis? No! He has a genetic leukodystrophy and has variants in the gene POLG (p.Thr251Ile and p.Pro587Leu). pubmed.ncbi.nlm.nih.gov/41925503/

Fasting Multiple Sclerosis Johns Hopkins Research youtube.com/shorts/HAnOJ...

Different approaches to the treatment of multiple sclerosis with disease modifying therapy in graphical form. pubmed.ncbi.nlm.nih.gov/41925508/

I'm Selling Out to Big Pharma youtu.be/K0wqXgprAi4?...

This Canadian study suggests a possible link between processed food and pediatric multiple sclerosis. "Each additional 10% in ultra-processed food consumption was associated with a 35% higher odds" (adjusted odds ratio [aOR]=1.35, 95% CI 1.05, 1.73) pubmed.ncbi.nlm.nih.gov/41916081/

Query for the neurologists. Healthy 37-year-old male. Incidental asymptomatic right middle cerebral artery stenosis noted on a Prenuvo scan. What is your recommendation?

A schematic on how nutrition could affect the pathogenesis of multiple sclerosis pubmed.ncbi.nlm.nih.gov/41892626/

MRI brain findings in multiple sclerosis. T2 lesions (A), black holes (B), paramagnetic rim lesions (C), and the central vein sign (D) pubmed.ncbi.nlm.nih.gov/41884359/

meta analysis of 17 studies on b-cell depleters (rituximab, briumvi, ocrevus) standard vs. extended interval dosing (taking it less often) have comparable results in terms of relapse rates and MRI activity, though no major difference in serious infections pubmed.ncbi.nlm.nih.gov/41890616/

Risk of "rebound" relapse after stopping zeposia for multiple sclerosis. It was 30.6% within two months for 1679 participants who did not start commercial zeposia at the end of the DAYBREAK single arm open label extension trial. Most relapses not severe. pubmed.ncbi.nlm.nih.gov/41891136/

Dr. Shay Taylor-Allen matches in anesthesiology residency at Yale New Haven Hospital where she previously worked as a janitor! youtu.be/7zxMBRj8-I8?...

Multiple Sclerosis with Alexia without Agraphia youtube.com/shorts/jKjwh...

Tysabri vs. Tyruko for MS. Even though a randomized trial suggests these two natalizumab formulations are equivalent and drug levels remain stable after switching, some people are dissatisfied with the results and report more side effects. pubmed.ncbi.nlm.nih.gov/41861706/

Ketogenic Diet MS Research at University of Virginia youtube.com/shorts/SNaKz...

A woman was diagnosed with MS in 2019. A cerebrospinal fluid sample (obtained from spinal anaesthesia in a research study) 15 years prior showed antibodies against Epstein-Barr virus (EBV). A case report from Spain pubmed.ncbi.nlm.nih.gov/41841779/

Potential treatments of Epstein-Barr virus (EBV) which could be used in multiple sclerosis: vaccines, antivirals, immunotherapy. pubmed.ncbi.nlm.nih.gov/41846093/

Using rituximab for multiple sclerosis as infrequently as every 18-24 months in those who were previously stable is associated low disease activity (MRI disease activity and/or relapses in only 2.4%. From Southern California, USA journals.sagepub.com/doi/10.1177/...

Innocare Pharma intends to begin research on an investigational multiple sclerosis drug ICP-538 which works by degrading VAV1 protein involved in the function of lymphocytes (b and t cells) multiplesclerosisnewstoday.com/news-posts/2...

What actually happens to people with MS 6 years after starting mavenclad. 63.2% remain free of any new treatments (data from Germany) after the initial two annual courses, but other receive further mavenclad courses or a different drug. link.springer.com/article/10.1...

Fenebrutinib Update. Clinical Trial Results, Liver Disease, and Death: www.youtube.com/watch?v=xSFm...

Multiple sclerosis prevalence and race. Data from the All of Us Research Program. pubmed.ncbi.nlm.nih.gov/41833242/

The prevalence of multiple sclerosis in Lithuania is about 1 in 800. pmc.ncbi.nlm.nih.gov/articles/PMC...

Multiple Sclerosis is still extremely rate in Korea with a prevalence of only 1 in 29,000 pubmed.ncbi.nlm.nih.gov/41818658/

Can hematopoietic stem cell transplant, perhaps the strongest disease modifying therapy in MS, reverse paramagnetic rim lesions on 7T MRI? According to this small case series (n = 7), no. None of the lesions resolved. pubmed.ncbi.nlm.nih.gov/41821410/

The risk of shingles with different multiple sclerosis disease modifying therapies. The risk is highest with gilenya, Lemtrada, and Mavenclad. Ocrevus/Kesimpta surprisingly were not linked to increased risk. pubmed.ncbi.nlm.nih.gov/41823332/

Invisible Symptoms in "Benign" Multiple Sclerosis youtube.com/shorts/MTyBg...

Multiple Sclerosis & Kappa Free Light Chains Explained youtu.be/6HN4HKfj5NE?...

My analysis of excess deaths with fenebrutinib in the FENhance 1/2 and FENtrepid trials suggests this would be extremely unlikely to occur by random chance. By X^2, p-value is 0.0016. By Fisher exact, p ~ 0.0019. But why?

Liver enzymes in the FENtrepid Trial (fenebrutinib vs. ocrevus in primary progressive MS). Much more liver enzyme elevation with fenebrutinib as expected, though all cases resolved after stopping the drug and none lead to permanent liver failure. assets.roche.com/f/176343/x/4...

Deaths in the FENtrepid Trial (fenebrutinib vs. ocrevus in primary progressive MS). 7 deaths with fenebrutinib vs. only one with Ocrevus. Concerning, but there is no specific pattern. assets.roche.com/f/176343/x/4...

It is a pity we didn't do it before the new McDonald diagnostic criteria were developed. The process is underpinned by Viquar Chamoun's work on neurosarcoidosis as part of his MD. Beyond the 2024 McDonald Criteria for Defining and Diagnosing Multiple Sclerosis buff.ly/u6HBOkS

FENtrepid (Fenebrutinib vs. ocrevus in PPMS). compositive disability similar. nonsignificant trend favoring fenebrutinib. HR: 0.88 (95% CI 0.75–1.03) Data driven mostly by timed 25-foot-walk. 9-hole peg test favored fenebrutinib (26% less progression) assets.roche.com/f/176343/x/4...

Dr. Amit Bar-Or summarizes the primary results from the Phase III FENtrepid study of fenebrutinib versus ocrevus in primary progressive MS youtu.be/o3sxq3rnpsA?...

serum neurofilament light chain (a marker of central nervous system injury in multiple sclerosis) does not correlate with "no evidence of disease activity" (NEDA-3) in people who are taking disease modifying therapy. link.springer.com/article/10.1...